After 100 years with only one TB vaccine, four promising candidates are now in advanced clinical trials—and one just completed enrollment ahead of schedule.
Our interactive dashboard lets you track each candidate’s progress in real-time, from Gates Medical Research Institute’s $550M M72/AS01E trial to IAVI’s innovative MTBVAC vaccine derived from human TB strains.
With 10.7 million new TB cases reported in 2024, these vaccines represent humanity’s best chance to finally defeat this ancient killer. Explore the science, follow the funding, and watch history unfold.